FOXO4-DRI
Also known as: FOXO4-D-Retro-Inverso, FOXO4-p53 interfering peptide, cell-permeable FOXO4-p53 interfering peptide, FOXO4 DRI, retro-inverso senolytic peptide
Senolytic peptide (D-retro-inverso peptide / cell-penetrating peptide)
What it is
FOXO4-DRI is a senolytic peptide being studied in animals for its ability to selectively eliminate aged, dysfunctional cells that accumulate with age and drive chronic inflammation. It works by triggering a form of cell death specifically in these senescent cells. Not FDA-approved; no human trials; evidence comes from animal studies.
The scientific side
FOXO4-DRI is an all-D-amino-acid retro-inverso peptide designed to disrupt the interaction between FOXO4 and p53. Under normal senescent-cell physiology, FOXO4 binds p53 in nuclear bodies and sequesters it, preventing p53 from inducing apoptosis and thereby maintaining senescent cell viability. FOXO4-DRI competitively interferes with this FOXO4–p53 interaction; structural NMR studies show that the disordered FOXO4-DRI binds the disordered p53 transactivation domain and forms a transiently folded complex, with p53 phosphorylation enhancing binding affinity. By displacing FOXO4, the peptide promotes nuclear exclusion of phosphorylated p53 (PMID 39994346; PMID 41625068), which subsequently activates pro-apoptotic effectors including BAX and cleaved caspase-3 via the p53/BCL-2/Caspase-3 pathway, selectively inducing apoptosis in senescent cells while leaving non-senescent (healthy) cells largely unaffected (PMID 28340347; PMID 42024235).
Class: Senolytic peptide (D-retro-inverso peptide / cell-penetrating peptide)
Administration & storage
- Administration
- Intraperitoneal injection — used in neonatal rat BPD model (PMID: 37874230)Injection in aged and progeroid mice for vascular aging studies — route not further specified beyond 'injection' (PMID: 41625068)In vitro direct cell treatment — keloid organ cultures and fibroblasts (PMID: 39994346)In vitro direct cell treatment — expanded chondrocytes (PMID: 33996787)In vitro direct cell treatment — senescent Leydig cells (PMID: 31959736)
- Storage
- No abstract in the reviewed literature explicitly describes storage conditions for FOXO4-DRI.
- Cautions
- FOXO4-DRI has not been clinically validated in humans; all efficacy and safety data are from preclinical (animal and in vitro) models.,Senolytic clearance of senescent pulmonary endothelial cells with FOXO4-DRI worsened pulmonary hemodynamics in animal models of pulmonary hypertension, indicating potential context-dependent harm.,Long-term toxicology, pharmacokinetics, and delivery studies for FOXO4-DRI have not been reported in the reviewed literature; clinical translation requires such data.,Disruption of p53-dependent tumor surveillance is a theoretical risk of FOXO4-p53 axis interference that requires explicit assessment.,Sterile technique is essential for any injectable peptide preparation to minimize infection risk.
Legal & regulatory status
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
Not stated in reviewed literature — requires manual verification
What it's studied for
- Brain aging and cognitive decline / neurodegeneration Animal studies only
- Review reports that in aged mammalian models, FOXO4-DRI decreases accumulation of senescent cells, restores cerebral blood flow and blood-brain barrier integrity, reverses hippocampal atrophy, and enhances cognitive function. In Alzheimer's disease and tauopathy models, treatment eliminated amyloid-β and pathological t PMID 42024235 Alameen et al., Naunyn-Schmiedeberg's Arch Pharmacol (2026)
- Glioblastoma treatment sensitization (enhancing temozolomide efficacy) In vitro only
- FOXO4-DRI, used as a senolytic agent, enhanced the therapeutic efficacy of temozolomide by eliminating senescent GBM cells via apoptosis in cell line experiments. PMID 42391447 Ning et al., Mol Carcinogen (2026)
- Keloid fibroblast senescence and apoptosis resistance In vitro only
- FOXO4-DRI promoted apoptosis and decreased G0/G1 phase cells in pro-senescence models of keloid organ cultures and fibroblasts, accompanied by p53-pS15 nuclear exclusion. Showed potential as a treatment targeting senescence and apoptosis resistance in keloids. PMID 39994346 Kong et al., Commun Biol (2025)
- Vascular aging / endothelial cell senescence Mixed
- Injection of FOXO4-DRI in naturally aged and progeroid model mice suppressed aortic aging and improved aortic function. In vitro, FOXO4-DRI alleviated OGD-induced endothelial cell senescence and enhanced endothelial cell function via the p53/BCL-2/Caspase-3 pathway. PMID 41625068 Hu et al., Front Bioeng Biotechnol (2025)
- Review notes FOXO4-DRI has shown senolytic activity in preclinical models including vascular endothelium, but has not been clinically validated. PMID 42510573 Mateescu et al., Antioxidants (2026)
- Bronchopulmonary dysplasia (BPD) Animal studies only
- Foxo4-DRI administered intraperitoneally at postnatal days P4, P6, P8, and P10 in hyperoxia-exposed rat pups led to outcomes similar to TUDCA and KYC interventions: decreased cellular senescence and improved alveolar complexity. PMID 37874230 Jing et al., Am J Respir Cell Mol Biol (2024)
- Non-small cell lung cancer radiosensitization and radiation-induced pulmonary fibrosis Mixed
- Specific induction of senescence-like CAF apoptosis using FOXO4-DRI resulted in radiosensitization of NSCLC cells in vitro and in vivo, and also demonstrated therapeutic effect on alleviating radiation-induced pulmonary fibrosis by targeting senescence-like fibroblasts in vivo. PMID 34877934 Meng et al., JCI Insight (2021)
- Pulmonary fibrosis (bleomycin model) Animal studies only
- FOXO4-DRI therapeutic administration in BLM-induced PF mice showed milder pathological change and less collagen deposition compared with BLM-alone group; reset intranuclear p53 distribution and decreased total ECM protein content. PMID 37074394 Liu et al., Naunyn-Schmiedeberg's Arch Pharmacol (2023)
- FOXO4-DRI decreased senescent cells, downregulated SASP, attenuated BLM-induced morphological changes and collagen deposition in mice, increased AEC2 and fibroblast percentages, and decreased myofibroblasts. Showed preference for killing TGF-β-induced myofibroblasts in vitro. PMID 35510614 Han et al., J Cell Mol Med (2022)
- Pulmonary arterial hypertension / senescent cell clearance Animal studies only
- FOXO4-DRI administration worsened pulmonary hemodynamics in murine pulmonary hypertension models by eliminating senescent pulmonary endothelial cells, suggesting context-dependent detrimental effects of senolysis in this disease setting. PMID 36515093 Born et al., Circulation (2023)
- Male late-onset hypogonadism / testosterone insufficiency Animal studies only
- FOXO4-DRI selectively induced apoptosis in senescent Leydig cells in vitro (H2O2-induced model) and improved the testicular microenvironment and alleviated age-related testosterone secretion insufficiency in naturally aged mice. PMID 31959736 Zhang et al., Aging (2020)
- Spermatogenesis improvement in aged males Animal studies only
- FOXO4-DRI induced apoptosis in senescent Leydig cells, reduced certain SASP secretion, improved proliferation of co-cultured GC-1 SPG cells, and in naturally aged mice, FOXO4-DRI-treated animals exhibited increased sperm quality and improved spermatogenesis. PMID 39025385 Li et al., Exp Gerontol (2024)
- Renal aging and transplantation outcomes Animal studies only
- Review reports that FOXO4-DRI peptide-induced forced apoptosis of senescent cells reduced age-associated damage and dysfunction in multiple organs, particularly the kidney, and increased performance and lifespan in experimental studies. PMID 29260442 Valentijn et al., J Cell Commun Signal (2018)
- Review discusses FOXO4-DRI as part of a new class of anti-senescence compounds that have shown ability to restore tissue homeostasis in old mice and improve kidney function, with proposed application to improve donor kidney quality and transplantation outcomes. PMID 29471104 van Willigenburg et al., Pharmacol Res (2018)
- Cartilage tissue engineering / autologous chondrocyte implantation In vitro only
- FOXO4-DRI removed more than half of cells in high-passage (PDL9) expanded chondrocytes without significantly affecting low-passage (PDL3) cells. Pre-treatment reduced senescence level but did not enhance chondrogenic potential; cartilage tissue from treated PDL9 cells showed lower expression of senescence-relevant secr PMID 33996787 Huang et al., Front Bioeng Biotechnol (2021)
- General senescence clearance / rejuvenation Animal studies only
- Commentary on Baar et al. reports that FOXO4-DRI (all-D amino acid peptide) restores p53's apoptotic role in senescent cells and ameliorates consequences of senescence-associated loss of tissue homeostasis in animal models. PMID 28340347 Krimpenfort & Berns, Cell (2017)
Safety signals
- Senolytic clearance of senescent pulmonary endothelial cells by FOXO4-DRI was associated with worsened pulmonary hemodynamics (increased right ventricular systolic pressure, vessel remodeling, loss of pulmonary endothelial cells) in multiple murine pulmonary hypertension models and in rats given monocrotaline, suggesting that elimination of senescent cells in this vascular context may be harmful. PMID 36515093
- Clinical translation of FOXO4-p53 disruption requires isoform- and tissue-specific validation, pharmacokinetic and delivery studies, long-term toxicology, and explicit assessment of p53-dependent tumor surveillance; FOXO4-DRI has not been clinically validated. PMID 42510573
- No human safety or pharmacokinetic data for FOXO4-DRI were reported in any of the reviewed abstracts; all data derive from animal or in vitro experiments. PMID 42024235
Contraindications
- Pulmonary arterial hypertension or conditions dependent on senescent pulmonary endothelial cell populations: senolytic elimination of these cells with FOXO4-DRI worsened pulmonary hemodynamics in animal models. PMID 36515093
Protocol
1.5 mg subcutaneous injection, every other day (eod). Cycle: 3 injections (1 week total).
About these dose ranges
Dose ranges below reflect commonly reported community protocols. Where published research cites a specific dose, the PMID is linked. Doses without citations are not clinical recommendations — they reflect what practitioners and researchers commonly report using.
Community-reported dosing
| Route | Dose | Frequency / Duration | Population / context | Source tier |
|---|---|---|---|---|
| Intraperitoneal | Not explicitly stated (administered intraperitoneally at P4, P6, P8, and P10) | Postnatal days 4–10 (every other day) | animal | Research PMID 37874230 |
| Not explicitly stated in abstract | Not explicitly stated in abstract | Not explicitly stated in abstract | animal | Research PMID 34877934 |
| Not explicitly stated in abstract | Not explicitly stated in abstract | Not explicitly stated in abstract | animal | Research PMID 37074394 |
| Not explicitly stated in abstract | Not explicitly stated in abstract | Not explicitly stated in abstract | animal | Research PMID 35510614 |
| Not explicitly stated in abstract | Not explicitly stated in abstract | Not explicitly stated in abstract | animal | Research PMID 31959736 |
| Not explicitly stated in abstract | Not explicitly stated in abstract | Not explicitly stated in abstract | animal | Research PMID 39025385 |
| Injection (naturally aged and progeroid model mice) | Not explicitly stated in abstract | Not explicitly stated in abstract | animal | Research PMID 41625068 |
| In vitro treatment | Not explicitly stated in abstract | Not explicitly stated in abstract | in_vitro | Research PMID 33996787 |
| In vitro (keloid organ cultures and fibroblast cultures) | Not explicitly stated in abstract | Not explicitly stated in abstract | in_vitro | Research PMID 39994346 |
| subcutaneous injection | 1.5 mg | every other day (EOD) · 3 injections (1 week total) | biohackers and longevity-focused individuals experimenting with senolytic protocols | [Community] |
| subcutaneous injection | 1 mg | every other day (EOD) · 3 injections (1 week total) | biohackers new to FOXO4-DRI or those with lower body weight, experimenting with senolytic protocols | [Community] |
| subcutaneous injection | 2 mg | every other day (EOD) · 3 injections (1 week total) | experienced biohackers seeking more aggressive senolytic effect | [Community] |
| subcutaneous injection | 1.5 mg | every other day (EOD) · 3 injections per cycle, repeated quarterly (every 3 months) | longevity-focused biohackers running recurring senolytic maintenance cycles | [Community] |
| subcutaneous injection | 1.5 mg | every other day (EOD) · 3 injections per cycle, repeated every 6 months | longevity-focused biohackers preferring a more conservative repeat schedule | [Community] |
| subcutaneous injection | 0.5 mg | daily for 3 days · 3 days | biohackers attempting a low-dose ramp-up or tolerability test before committing to full protocol | [Community] |
All studies (17)
- PMID 34877934 Mixed
Non-small cell lung cancer radiosensitization and radiation-induced pulmonary fibrosis - PMID 41625068 Mixed
Vascular aging / endothelial cell senescence - PMID 42510573 Mixed
Vascular aging / endothelial cell senescence - PMID 28340347 Animal studies only
General senescence clearance / rejuvenation - PMID 29260442 Animal studies only
Renal aging and transplantation outcomes - PMID 29471104 Animal studies only
Renal aging and transplantation outcomes - PMID 31959736 Animal studies only
Male late-onset hypogonadism / testosterone insufficiency - PMID 33996787 In vitro only
Cartilage tissue engineering / autologous chondrocyte implantation - PMID 35510614 Animal studies only
Pulmonary fibrosis (bleomycin model) - PMID 36515093 Animal studies only
Pulmonary arterial hypertension / senescent cell clearance - PMID 37074394 Animal studies only
Pulmonary fibrosis (bleomycin model) - PMID 37874230 Animal studies only
Bronchopulmonary dysplasia (BPD) - PMID 39025385 Animal studies only
Spermatogenesis improvement in aged males - PMID 39994346 In vitro only
Keloid fibroblast senescence and apoptosis resistance - PMID 40593617
- PMID 42024235 Animal studies only
Brain aging and cognitive decline / neurodegeneration - PMID 42391447 In vitro only
Glioblastoma treatment sensitization (enhancing temozolomide efficacy)
Frequently asked
What is FOXO4-DRI and how does it work?
FOXO4-DRI is an all-D-amino-acid retro-inverso peptide designed to disrupt the interaction between the FOXO4 protein and p53. In senescent cells, FOXO4 sequesters p53 in nuclear bodies to prevent apoptosis; FOXO4-DRI competitively binds the p53 transactivation domain, promotes nuclear exclusion of phosphorylated p53, and activates pro-apoptotic signaling (BAX, caspase-3), selectively killing senescent cells while sparing healthy ones (PMID 28340347; PMID 40593617; PMID 41625068).
What conditions or diseases has FOXO4-DRI been studied for?
Preclinical studies have investigated FOXO4-DRI in models of brain aging and cognitive decline, pulmonary fibrosis (PMID 37074394; PMID 35510614), non-small cell lung cancer radiosensitization, vascular/endothelial aging, bronchopulmonary dysplasia, Leydig cell senescence and testosterone insufficiency, spermatogenesis, keloid fibroblasts, and cartilage tissue engineering. All evidence is preclinical (animal or in vitro); no human clinical trials are reported in the reviewed literature.
Has FOXO4-DRI been tested in humans?
No human clinical trial data for FOXO4-DRI are reported in the reviewed abstracts. One review notes it has not been clinically validated. All published efficacy and safety data come from animal models or in vitro experiments.
What dose of FOXO4-DRI should I take?
I'm not a medical professional and can't recommend a protocol for you specifically. What research has shown: the reviewed abstracts describe FOXO4-DRI use in animal and in vitro studies (e.g., intraperitoneal injection in neonatal rat models [PMID 37874230]), but specific dose amounts are not stated in the available abstracts. No human dosing data exist in the reviewed literature.
Is FOXO4-DRI safe to use?
Safety data in humans are absent from the reviewed literature. Key preclinical safety signals include: (1) worsening of pulmonary hemodynamics when senescent pulmonary endothelial cells were cleared with FOXO4-DRI in animal models of pulmonary hypertension; (2) theoretical risk of impairing p53-dependent tumor surveillance; (3) absence of pharmacokinetic, long-term toxicology, and clinical validation data. Please consult a licensed healthcare provider.
Can I stack FOXO4-DRI with other senolytics or compounds?
I can't recommend combining compounds — that's a prescribing decision. Here's what has been studied individually: FOXO4-DRI has been studied as a standalone senolytic in preclinical models (PMID 28340347; PMID 37074394). One study compared it with other agents (TUDCA, KYC) in a BPD model but tested them separately, not in combination.
Where can I buy FOXO4-DRI?
I don't recommend vendors or sources. Please consult a licensed provider.
Can FOXO4-DRI treat my osteoarthritis or joint pain?
I can't suggest treatments for medical conditions. Please speak with a licensed healthcare provider. For context, one in vitro study explored FOXO4-DRI for removing senescent cells from expanded chondrocytes used in cartilage repair procedures, but found it did not enhance chondrogenic potential and noted further investigation is needed. No human data exist.
Does FOXO4-DRI have anti-aging effects?
In preclinical models, FOXO4-DRI has been reported to clear senescent cells and improve tissue function in aged animals, including effects on testosterone levels, spermatogenesis, vascular function, and cognitive measures. However, all data are from animal or in vitro studies; the peptide has not been clinically validated in humans.
Are there any situations where FOXO4-DRI could be harmful?
Yes — published animal research found that FOXO4-DRI worsened pulmonary hemodynamics in models of pulmonary arterial hypertension by eliminating senescent pulmonary endothelial cells. Reviewers also highlight theoretical risks to p53-dependent tumor surveillance and the need for long-term toxicology data before any clinical use. No human safety data are available in the reviewed literature.